Figure 2.

MYST1 silencing inhibits cell proliferation in GBM cells. A, Quantitative real‐time PCR (qRT‐PCR) and western blot analysis of MYST1 mRNA and protein expression in several GBM cell lines. B, qRT‐PCR and Western blot analysis of MYST1 mRNA and protein expression in LN229, U87 and A172 cells after MYST1/GFP silencing. C, MTT assay reveals significant cell proliferation inhibition induced by MYST1 silencing in LN229, U87 and A172 cells, compared to that of the GFP silencing group (n = 3). D, Cell counting by trypan blue assay reveals significant cell proliferation inhibition induced by MYST1 silencing in LN229, U87 and A172 cells, compared to that of the GFP silencing group (n = 3). E, BrdU‐positive cells in LN229, U87 and A172 after MYST1/GFP silencing. All data were used as mean ± SD, n ≥ 3, significant difference was tested by Student's t test. *P < .05, **P < .01, ***P < .001. P < .05 was considered as statistically significant. GBM, glioblastoma; GFP, green fluorescent protein